BioCryst Halts Trials For BCX9930 Due To Safety Concerns
Executive Summary
Biotech stops enrollment in three Phase II studies of oral Factor D inhibitor BCX9930 after seeing elevated creatinine levels. The halt is voluntary, and enrolled patients can continue dosing, BioCryst says.